Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL12813166 | 0.98 | HTR3A (0.47) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| Iodide SCHEMBL12813168 | 0.96 | HTR3A (0.46) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| SCHEMBL30165715 | 0.90 | KMT2A (0.50) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| SCHEMBL146313 | 0.90 | KMT2A (0.50) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| Iodide SCHEMBL11279046 | 0.88 | KMT2A (0.48) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL40555 | 0.88 | MAPT (0.50) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| SCHEMBL50667 | 0.81 | MAPT (0.56) | ALDH1A1MAPTKDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL12620639 | 0.79 | KDM4E (0.43) | ALDH1A1MAPTKDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL11281816 | 0.79 | ALDH1A1 (0.44) | HTR3AALDH1A1MAPTKDM4EHSD17B10 | |
| Iodide SCHEMBL1471059 | 0.79 | MAPT (0.53) | ALDH1A1MAPTKDM4EHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699241-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-8828986-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2699241-A1 | ANTIVIRAL COMPOUNDS | Prosetta Antiviral Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012145567-A1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270854-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012135402-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120238543-A1 | Antiviral Compounds | Prosetta Antiviral, Inc. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012125983-A1 | ANTIVIRAL TREATMENTS | PROSETTA ANTIVIRAL INC. (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238543-A1 | Antiviral Compounds | MAVS, EIF2AK2, IRF3 | HTR3A 459/4885ALDH1A1 2519/4885MAPT 1842/4885 |
| US-20120270854-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | HTR3A 3128/4885ALDH1A1 1002/4885MAPT 1569/4885 |
| US-20120302556-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | HTR3A 3128/4885ALDH1A1 1002/4885MAPT 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.